GSK’s cancer drug Jemperli gets file acceptance from US FDA

GlaxoSmithKline, GSK

GSK’s cancer drug Jemperli gets file acceptance from US FDA

June 6 (Reuters) – GSK (GSK.L) said on Tuesday that the U.S. Food and Drug Administration had granted file acceptance for its cancer drug, Jemperli, when combined with chemotherapy to treat adult patients with certain types of endometrial cancer.

Reporting by Radhika Anilkumar in Bengaluru; Editing by Savio D’Souza

Our Standards: The Thomson Reuters Trust Principles.

Source: Reuters

/by
You might also like
Johnson & JohnsonUS FDA classifies recall of J&J’s electrosurgical tools as most serious
ZantacDrugmakers’ shares stabilize after Zantac litigation slump
AbbottAbbott receives FDA clearance for whole blood rapid test to help with assessment of concussion at the patient’s bedside
Lane Degenhart, AbelsonTaylorAbelsonTaylor Group names Lane Degenhart as vice president, account director
Johnson & JohnsonJ&J wins full FDA approval for Rybrevant, chemo combo in NSCLC
AstraZenecaFDA OKs Imfinzi as first immunotherapy for advanced biliary tract cancer
MerckNew ALS treatments face regulatory uncertainty
MerckMerck’s endometrial cancer therapy fails trial